ELC : Investigator Insights: VEGF and VEGFR Inhibitors in Gynecologic Malignancies

  Blogger's Note: requires registration

CME expires 2013

Investigator Insights: VEGF and VEGFR Inhibitors in Gynecologic Malignancies

Preclinical and clinical investigations provide a strong rationale for the use of angiogenesis inhibitors in ovarian primary peritoneal/fallopian tube cancer, and a large variety of angiogenesis inhibitors are in late stages of development. Drs. Thomas Herzog and Robert Burger discuss VEGF and VEGFR inhibitors including emerging data from clinical trails, management of toxicities and the future direction of this field.